Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Growth Hormone Deficiency

Growth Hormone Deficiency

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Growth Hormone Deficiency

21 trials tracked for Growth Hormone Deficiency: 15 in phase 3 or 4 and 2 with published results. The most-cited published study has 36 citations.

21Trials tracked
15Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 8 Phase 3 7 Phase 2 4 Other / NA 2
  1. Phase 4 Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN® Completed · 36 cited
  2. Phase 3 Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency Completed · 4 cited
  3. Phase 4 Anterior Pituitary Hormone Replacement in Traumatic Brain Injury Completed
  4. Phase 4 Growth Hormone and Endothelial Function in Children Completed
  5. Phase 4 A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency Completed
  6. Phase 4 Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia Completed
Show 15 more trials
  1. Phase 4 Easypod United States User Trial Completed
  2. Phase 4 A Study to Optimize Growth Hormone Dosing in Children With Chronic Kidney Disease by Measuring IGF-1 Levels in Blood Completed
  3. Phase 4 Comparison of a Needle-free Injection Method With a Needle-syringe Injection Method Completed
  4. Phase 3 Patient Perception of Treatment Burden in Weekly Versus Daily Growth Hormone Injections in Children With GHD Completed
  5. Phase 3 A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency Completed
  6. Phase 3 Efficacy and Safety of a High Dosage Compared to the Label Dosage of Somatropin in Early Pubertal Stage Children With Growth Hormone Deficiency Completed
  7. Phase 3 Genotropin Study Assessing Use of Injection Pen Completed
  8. Phase 3 Evolution Of Growth Rate In Children With Growth Retardation Due to Glucocorticosteroid Therapy And Treated By Genotonorm Completed
  9. Phase 3 Cross Over Convenience And Preference Study Of New Mark VII Compared To Genotropin Pen In Pediatric And Adult Subjects Completed
  10. Phase 2 Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese Completed
  11. Phase 2 Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213) Completed
  12. Phase 2 Testosterone and Growth Hormone for Bone Loss in Men Completed
  13. Phase 2 Growth Hormone Deficiency in Chronic Heart Failure: A Preliminary Trial Completed
  14. N/A A Prospective Non-Interventional Study Protocol With Primary Data Collection - Assessment Of The Long Term Treatment Outcomes Of Genotropin Treatment In Growth Hormone Deficiency (GHD) Patients Completed
  15. N/A Effects of Growth Hormone Administration on Cardiovascular Risk in Cured Acromegalics With Growth Hormone Deficiency Completed

Showing the 21 most-cited and recently-updated of 21 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Growth Hormone Deficiency: what the trials found

Several growth hormone therapies have demonstrated significant impacts on physiological markers. Saizen was associated with a significant increase in Insulin Like Growth Factor-1 Standard Deviation Score (IGF-1 SDS) at month 1 (p<0.0001) 2. Somatropin treatment showed specific outcomes regarding immune response, with only 3.7% of participants developing anti-GH antibodies and 0% exhibiting neutralizing antibodies 3.

Clinical improvements in growth metrics have been observed across various formulations. MOD-4023 demonstrated measurable changes in Height Standard Deviation Score (SDS) after 12 months 10, while Nutropin AQ was associated with a change in height of 10.3 at 56 weeks 7. Somatropin also showed significant improvements in Height SDS for Chronological Age at month 36 13.

Metabolic and body composition changes were noted with specific treatments: Lonapegsomatropin resulted in a significant reduction in trunk percent fat at week 38 (p<0.0001) 11, while growth hormone was associated with significant changes in glucose (p=0.018) and insulin (p=0.04) 4.

Patient experience and administration ease were evaluated for Genotropin products; studies showed that a majority of dyads reported the New Genotropin Mark VII Injection Pen as being easier to use or having no difference compared to previous versions [14, 15].

Recent results — preliminary, needs further review

  • LUM-201 was associated with an increase in Height SDS (0.08229), Weight SDS (0.62279), and BMI SDS (0.32057) 1.

For the clinician treating this condition

  • Saizen is effective for increasing IGF-1 levels at one month post-initiation 2.
  • Somatropin treatment is associated with a low incidence of anti-GH antibodies and no neutralizing antibodies 3.
  • Lonapegsomatropin significantly reduces trunk percent fat by week 38 11.
  • Newer delivery systems, such as the Genotropin Mark VII Injection Pen, are reported as easy to use by a majority of patients and caregivers [14, 15].

AI synthesis of 8 cited trials, updated Jun 22, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Narrative review compares long-acting growth hormone to daily recombinant human GH in pediatric GH deficiency
Diabetes & Endocrinology Sys. Review
Narrative review compares long-acting growth hormone to daily recombinant human GH in pediatric GH deficiency Long-acting growth hormone matches daily shots for growing children with hormone deficiency
This narrative review evaluates long-acting growth hormone formulations versus daily recombinant human GH for pediatric patients with GH def…
A review found long-acting growth hormone works as well as daily shots for kids with growth hormone deficiency while keeping safety profiles…
Frontiers May 23, 2026
FDA Approves Ngenla (somatrogon-ghla) for Pediatric Growth Hormone Deficiency
Pediatrics FDA Approval
FDA Approves Ngenla (somatrogon-ghla) for Pediatric Growth Hormone Deficiency FDA approves once-weekly growth hormone drug Ngenla for children
FDA approved Ngenla (somatrogon-ghla) for treatment of pediatric patients aged 3 years and older with growth failure due to inadequate secre…
The FDA approved Ngenla (somatrogon-ghla), a once-weekly injection for children 3 and older with growth failure due to low growth hormone. I…
FDA May 5, 2026
Meta-analysis indicates increased BMI SD scores with long-acting growth hormone versus daily rhGH in children
Pediatrics Meta-analysis
Meta-analysis indicates increased BMI SD scores with long-acting growth hormone versus daily rhGH in children New Growth Hormone Treatment Tied to Weight Gain in Kids
This meta-analysis evaluated body mass index (BMI) SD scores in 585 children with growth hormone deficiency treated with long-acting growth …
This treatment could change how kids grow — but it might also affect their weight.
Apr 22, 2026
Review of arginine and levodopa stimulation testing reports hematuria in pediatric patients
Pediatrics Sys. Review
Review of arginine and levodopa stimulation testing reports hematuria in pediatric patients Red urine after a growth test? Here is what you need to know
This case report and literature review examines hematuria associated with combined arginine and levodopa growth hormone stimulation testing …
A simple growth test can sometimes turn urine red, but it is not dangerous and resolves quickly with rest and water.
Frontiers Apr 15, 2026

Questions about Growth Hormone Deficiency

Why did the FDA approve Ngenla for pediatric patients with Growth Hormone Deficiency?

The FDA approved Ngenla (somatrogon) for pediatric growth hormone deficiency because it is a long-acting treatment that allows for less frequent dosing, which can improve how often children and caregivers take the medicine.

Full answer →
What are the side effects of the stimulation test used to diagnose Growth Hormone Deficiency?

Growth hormone stimulation tests are generally safe, but rare side effects like blood in the urine can occur after arginine tests, and dexamethasone tests may cause drowsiness.

Full answer →
Is Ngenla approved for treating Growth Hormone Deficiency in children aged 3 years and older?

Yes, Ngenla is approved for treating growth hormone deficiency in children aged 3 years and older.

Full answer →
How does long-acting growth hormone compare to daily shots for kids with Growth Hormone Deficiency?

Long-acting growth hormone allows for less frequent dosing and improves adherence in children with growth hormone deficiency, while showing similar safety and growth effects compared to daily shots.

Full answer →